Off-the-Shelf CAR t cells take on tough blood cancers

NCT ID NCT05995015

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and see if the cells shrink tumors, enrolling 30 participants across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Universal CD19-specific CAR T cells (4SCAR19U)
What this could lead to: If it works, this could lead to a more accessible 'off-the-shelf' CAR T cell therapy for people with hard-to-treat B cell cancers.
What could go wrong: This is a very early phase 1 trial with only 30 people. The therapy may not work, could cause severe side effects like cytokine release syndrome, and long-term control is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES

Contacts and locations

Locations

Shenzhen Geno-Immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.